A rare setback as Ozempic-maker Novo Nordisk takes a $820 million hit as its next wonder drug fails [Fortune]
BAYER AG S/ADR (BAYRY)
NASDAQ:AMEX Investor Relations:
investor.bayer.com
Company Research
Source: Fortune
The Danish drugmaker stopped the trial partway through, after an independent monitoring committee concluded that it hadn't hit its main goal of changing blood pressure after 12 weeks. The study of more than 600 patients, Clarion-CKD, had looked at the compound ocedurenone in patients with uncontrolled high blood pressure and advanced chronic kidney disease. Novo agreed last year to pay KBP BioSciences as much as $1.3 billion for ocedurenone, part of the Ozempic maker's effort to expand from its core diabetes treatment portfolio into other serious diseases. The failure is a rare setback for Novo, which is riding high on the success of its obesity drugs. The drugmaker had envisioned ocedurenone addressing a major need for people with both heart disease and chronic kidney disease, its executives said when the deal was announced in October. The company had planned to study the compound across different types of heart and kidney disease. Novo is now re-evaluating that plan, it said
Show less
Read more
Impact Snapshot
Event Time:
BAYRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BAYRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BAYRY alerts
High impacting BAYER AG S/ADR news events
Weekly update
A roundup of the hottest topics
BAYRY
News
- Redd Kross co-founder Steve McDonald talks about band's new album [CBS News]CBS News
- Bayer's (BAYRY) AskBio Advances Parkinson Disease Study [Yahoo! Finance]Yahoo! Finance
- AskBio Initiates Recruitment to its Phase 2 Parkinson's Disease Trial [Yahoo! Finance]Yahoo! Finance
- Pyrethrin Market Forecast to Hit $1.26 Billion by 2033: The Brainy Insights [Yahoo! Finance]Yahoo! Finance
- Endometriosis Drug Pipeline Landscape 2024: Insights About 15+ Companies and 20+ Pipeline Drugs [Yahoo! Finance]Yahoo! Finance